Related Experiment Video
Updated: Dec 26, 2025

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
Functions of Exogenous RUNX2 in Giant Cell Tumor of Bone In Vitro
Yuan-Han Jin1, Jing Zhang2, Hao Zhu3
1Department of Orthopaedic, Jinling Hospital, Southeast University, Medical School, Nanjing, China.
Objectives:
This research aimed to investigate the relative level of Runt-related transcription factor 2 (RUNX2) in giant cell tumor of bone (GCTB). Through the histopathological similarities between osteoporosis and GCTB, the biological functions of exogenous RUNXS were demonstrated in GCTB cell lines. This generated awareness of the molecular mechanism of the biogenesis and metastasis of GCTB, as well as showing the pathways and processes involved in this study. This research also expected to provide hints for the clinical treatment of patients with GCTB, to release the tumor burden and reduce the recurrence rate and metastasis of patients with this condition.
Methods:
The expression of RUNX2 in the tumors was verified by Western Blot, qRT-PCR and immunohistochemistry, compared with the normal tissues' adjacent tumors. Subsequently, the plasmids expressing RUNX2 were constructed, amplified and transfected into the 0404 cell line through transfection kits (0.4, 0.8, 1.6, 2.4 ng/μl). After that, the proliferation, migration, invasion, cellular viability and apoptosis of 0404 cell lines were examined by EDU assay, wound healing assay, transwell assay, annexin v staining, and CCK8 assay, respectively.
Results:
The messenger RNA (mRNA) level of RUNX2 in tumors was over 100 folds more than the normal tissues. The protein level of tumors upregulated 8.32(±4.41) folds relatively. After the transfection of RUNX2 overexpressed plasmids into the 0404 cell line, the mRNA level of RUNX2 increased approximately 530.11(±24.87), 1117.96(±77.68), 2835.09(±45.22) and 4781.51(±79.37) folds respectively, and the protein level was upregulated about 4.12(±1.15), 16.73(±1.63), 21.53(±2.41) and 23.39(±0.85) folds respectively. The proliferation of 0404 cells was inhibited by 2.13(±1.02)% of 1.6 ng/μl group and 3.03(±1.76)% of 2.4 ng/μl group. And the migration was inhibited about 45.56(±6.13)%, 50.79(±5.27)%, 63.15(±8.62)% and 93.90(±3.65)% respectively. The invasion was decreased about 14.49(±5.4)%, 37.02(±6.52)%, 42.24(±2.59)% and 48.97(±10.61)% respectively. Meanwhile, FITC Annexin V/PI apoptosis assay demonstrated that RUNX2 plasmids could promote apoptosis rate around 4.15(±0.27)%, 5.07(±0.27)%, 7.61(±0.45)% and 11.32(±1.02)% respectively, and CCK8 proved these plasmids could weaken cellular viability in a concentration-dependent manner with the time passing.
Conclusions:
RUNX2 is highly expressed in giant cell tumors of bone. The RUNX2 overexpressed plasmids we constructed could be successfully transfected into 0404 cell line. Far more importantly, the exogenous RUNX2 can seriously block the biological functions of 0404 cell line in a concentration-dependent manner, including proliferation, translocation, invasion, cellular viability, and apoptosis. Meanwhile, the mechanism was hypothesized and discussed in the article.
Insights
Runt-related transcription factor 2 (RUNX2) is highly expressed in giant cell tumors of bone (GCTB). Introducing exogenous RUNX2 into GCTB cells inhibited their proliferation, migration, invasion, and viability while promoting apoptosis, suggesting therapeutic potential.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Giant cell tumor of bone (GCTB) is a primary bone tumor with unpredictable behavior.
- Histopathological similarities exist between GCTB and osteoporosis, suggesting shared biological pathways.
- Understanding the molecular mechanisms of GCTB biogenesis and metastasis is crucial for effective treatment.
Purpose of the Study:
- To investigate the expression level of Runt-related transcription factor 2 (RUNX2) in GCTB.
- To elucidate the biological functions of exogenous RUNX2 in GCTB cell lines.
- To explore potential therapeutic strategies for GCTB by targeting RUNX2.
Main Methods:
- Quantitative real-time PCR (qRT-PCR), Western Blot, and immunohistochemistry were used to assess RUNX2 expression in GCTB tissues.
- RUNX2-overexpressing plasmids were constructed and transfected into the 0404 GCTB cell line.
- Cellular proliferation, migration, invasion, viability, and apoptosis were evaluated using EDU assay, wound healing assay, Transwell assay, Annexin V/PI staining, and CCK8 assay.
Main Results:
- RUNX2 mRNA and protein levels were significantly upregulated in GCTB tissues compared to normal adjacent tissues.
- Transfection of RUNX2-overexpressing plasmids into 0404 cells led to a dose-dependent increase in RUNX2 expression.
- Exogenous RUNX2 significantly inhibited cell proliferation, migration, invasion, and viability, while concurrently promoting apoptosis in a concentration-dependent manner.
Conclusions:
- RUNX2 is highly expressed in GCTB and its overexpression plays a significant role in GCTB pathogenesis.
- Successfully transfected RUNX2-overexpressing plasmids into GCTB cells.
- Exogenous RUNX2 effectively suppressed key biological functions of GCTB cells, indicating its potential as a therapeutic target.
More Related Videos
09:16Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
Published on: September 1, 2019
09:37A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation
Published on: March 15, 2018